Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group.
Fiche publication
Date publication
janvier 2019
Journal
The oncologist
Auteurs
Membres identifiés du Cancéropôle Est :
Pr KURTZ Jean-Emmanuel, Pr MALOUF Gabriel
Tous les auteurs :
Malouf GG, Beinse G, Adam J, Mir O, Chamseddine AN, Terrier P, Honore C, Spano JP, Italiano A, Kurtz JE, Coindre JM, Blay JY, Le Cesne A
Lien Pubmed
Résumé
Alveolar soft part sarcoma (ASPS) is a rare sarcoma characterized by a slow evolution, brain metastasis (BM), and resistance to doxorubicin. Antiangiogenic therapies (AAT) have shown clinical activity, but little is known about the optimal therapeutic strategy, specifically considering BM.
Mots clés
Alveolar soft part sarcoma, Angiogenesis inhibitors, Neoplasm drug resistance, Neoplasm metastasis
Référence
Oncologist. 2019 Jan 9;: